司美格鲁肽的勘误：它似乎比其他胰高血糖素样肽-1受体激动剂更有效。 （注：原文表述不太准确规范，正常可能会说“Semaglutide seems to be more effective than other GLP-1 receptor agonists.” ）
Erratum to semaglutide seems to be more effective the other GLP-1Ras.
作者信息
Holst Jens Juul, Madsbad Sten
机构信息
Department of Biomedical Sciences, Copenhagen University Hospital Hvidovre, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Department of Endocrinology, Copenhagen University Hospital Hvidovre, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
出版信息
Ann Transl Med. 2018 Feb;6(3):74. doi: 10.21037/atm.2018.01.20.
Abstract
[This corrects the article on p. 505 in vol. 5, PMID: 29299466.].
摘要
[这更正了第5卷第505页上的文章， PMID: 29299466。]
相似文献
1
Erratum to semaglutide seems to be more effective the other GLP-1Ras.司美格鲁肽的勘误：它似乎比其他胰高血糖素样肽-1受体激动剂更有效。 （注：原文表述不太准确规范，正常可能会说“Semaglutide seems to be more effective than other GLP-1 receptor agonists.” ）
Ann Transl Med. 2018 Feb;6(3):74. doi: 10.21037/atm.2018.01.20.
2
Clinical potential of treatment with semaglutide in type 2 diabetes patients.司美格鲁肽治疗2型糖尿病患者的临床潜力。
Drugs Context. 2019 Dec 2;8:212585. doi: 10.7573/dic.212585. eCollection 2019.
3
The Discovery and Development of Liraglutide and Semaglutide.利拉鲁肽和司美格鲁肽的发现与研发
Front Endocrinol (Lausanne). 2019 Apr 12;10:155. doi: 10.3389/fendo.2019.00155. eCollection 2019.
4
Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.胰高血糖素样肽-1 受体激动剂：用于治疗 2 型糖尿病的一类药物更新。
Can J Diabetes. 2017 Oct;41(5):524-535. doi: 10.1016/j.jcjd.2017.08.242.
5
GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms.糖尿病肾病中的胰高血糖素样肽-1受体激动剂：从临床结果到作用机制
Front Pharmacol. 2020 Jun 30;11:967. doi: 10.3389/fphar.2020.00967. eCollection 2020.
6
Semaglutide seems to be more effective the other GLP-1Ras.司美格鲁肽似乎比其他胰高血糖素样肽-1受体激动剂更有效。
Ann Transl Med. 2017 Dec;5(24):505. doi: 10.21037/atm.2017.11.10.
7
Cardiovascular safety and benefits of GLP-1 receptor agonists.胰高血糖素样肽-1受体激动剂的心血管安全性及益处
Expert Opin Drug Saf. 2017 Mar;16(3):351-363. doi: 10.1080/14740338.2017.1281246. Epub 2017 Jan 19.
8
Corrigendum.勘误
Paediatr Child Health. 2015 Nov-Dec;20(8):466-7. doi: 10.1093/pch/20.8.466.
9
An overview of new GLP-1 receptor agonists for type 2 diabetes.2型糖尿病新型胰高血糖素样肽-1受体激动剂概述
Expert Opin Investig Drugs. 2016;25(2):145-58. doi: 10.1517/13543784.2016.1123249. Epub 2015 Dec 17.
10
Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.肥胖型2型糖尿病的治疗策略：聚焦胰高血糖素样肽-1受体激动剂
Clin Ther. 2017 Jun;39(6):1244-1264. doi: 10.1016/j.clinthera.2017.03.013. Epub 2017 May 16.
引用本文的文献
1
Impact of Sodium -[8-(2-Hydroxybenzoyl)amino]-caprylate on Intestinal Permeability for Notoginsenoside R1 and Salvianolic Acids in Caco-2 Cells Transport and Rat Pharmacokinetics.8-(2-羟基苯甲酰基)氨基辛酸钠对 Caco-2 细胞转运和大鼠药代动力学中人参皂苷 R1 和丹酚酸的肠通透性的影响。
Molecules. 2018 Nov 16;23(11):2990. doi: 10.3390/molecules23112990.
本文引用的文献
1
Semaglutide seems to be more effective the other GLP-1Ras.司美格鲁肽似乎比其他胰高血糖素样肽-1受体激动剂更有效。
Ann Transl Med. 2017 Dec;5(24):505. doi: 10.21037/atm.2017.11.10.
Zotero 插件